Pharma Pulse 5/24/24: Counsel Patients on Nutrition and Following a Balanced Diet Complementary to GLP-1s, Neuralink’s First Brain-Implant Patient Stays Upbeat & more

Identifying Relevant Randomized Clinical Trial Questions for Hospitalized Children

Newly published consensus statement outlines RCT questions ranked according to importance and feasibility.

Counsel Patients on Nutrition and Following a Balanced Diet Complementary to GLP-1s

The GLP-1 market is expected to exceed $100 billion by 2023, according to J.P. Morgan Research, with total users in the United States projected to reach 30 million.

Despite Setback, Neuralink’s First Brain-Implant Patient Stays Upbeat

Elon Musk’s first human experiment with a computerized brain device developed significant flaws, but the subject, who is paralyzed, has few regrets.

Walgreens Boots Alliance Sells Shares of Cencora for $400 Million of Proceeds

Walgreens Boots Alliance, Inc. announced that it has sold shares of Cencora, Inc. pursuant to a share repurchase by Cencora in the amount of approximately $400 million. With the transaction, Walgreens Boots Alliance’s ownership of Cencora’s common stock has decreased from approximately 13% to approximately 12%.

Model N on LinkedIn:

Watch part three of Jesse Mendelsohn's video interview with Pharmaceutical Executive, where he discusses how more granular insights into channel, tracing, and chargeback data can help manufacturers make smarter provider and payer contracting decisions.

Check out part 1 and part 2 here:
Part 1️⃣:https://lnkd.in/davKm9zM
Part 2️⃣:https://lnkd.in/dZNJWhSp

Part 3️⃣ below. ⬇️

#ModelN #RevenueOptimization #RevenueManagementh #LifeSciences

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs